Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. - Wikidata - awgldk - TriplyDB

Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.

Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.

http://www.wikidata.org/entity/Q35382105

about

In Vivo pO2 Imaging of Tumors: Oxymetry with Very Low-Frequency Electron Paramagnetic Resonance Combining radiotherapy with sunitinib: lessons (to be) learned Vascular normalization and cancer immunotherapy Imaging tumor hypoxia to advance radiation oncology Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice Magnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism.In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences.Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin.Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.Antiangiogenic therapy for glioma.EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate Evaluation of partial k-space strategies to speed up time-domain EPR imaging CTA combined with CT perfusion for assessing the efficacy of anti-angiogenic therapy in rabbit VX2 tumors Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?Targeting the metabolic microenvironment of tumors.Combining two strategies to improve perfusion and drug delivery in solid tumors.Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment.Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.Modulation of immunity by antiangiogenic molecules in cancer.Tumor hypoxia as a driving force in genetic instability.Electron paramagnetic resonance: a powerful tool to support magnetic resonance imaging research.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.RIST: a potent new combination therapy for glioblastoma.Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.Tumor vascular microenvironment determines responsiveness to photodynamic therapy.Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.Pulsed Electron Paramagnetic Resonance Imaging: Applications in the Studies of Tumor Physiology.HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.

P2860

Q26782107-F773680A-1AAB-4652-BBEE-4AFF2B06723C Q26800587-C0D0D0E5-1B19-4D8C-80D9-85DD2DD51DF1 Q26827437-B9E538AB-FCAF-4D9B-B2F2-F82806106C97 Q27007862-0CA7E41D-6DA5-48B0-9F8E-59D72A6D9278 Q33639714-51A5E5C7-DDCD-4348-8F71-0E92F7AAFF22 Q33705268-312099DA-399E-4A3A-B614-6F6E1D6B1858 Q33738607-D8272D21-7A44-49A1-A465-56FC2F4761EF Q33746474-2BE4FC39-2411-4D66-AC67-397EB86669F1 Q33757106-7A02DB42-2E00-415C-A1D7-A4D106BD0555 Q33764933-57873348-9398-4BAA-8545-EB157AD1E29F Q34081980-B5390D9A-79E0-4CBA-A151-333FEFAFA95A Q34145257-6FEABC71-2811-43FA-9768-DA1763CE0AB8 Q34210210-C2BCE4B2-9A83-42C2-B35D-D024EB115423 Q34257226-CA0D6C43-074F-47EA-843B-FF33AE73F1DC Q34490050-46D0E9E0-7C08-4FEB-A9E7-A71CE903A05E Q35165488-BB6E68B0-F8B3-41B7-AC27-62A839467AA0 Q35955451-81ABF71D-1579-4AC4-A432-41AAEFC9C252 Q36101999-26C74661-C9EE-4556-8C3B-B1C78F3C99B5 Q36342034-027FD3A8-9761-4C02-82FC-74585F3A3827 Q36542544-AC7DE867-26EB-4D98-BB1B-CFE7223F83A1 Q36558272-3EBE86A8-50DC-4CFF-AD8A-04D85B492354 Q37132414-7D843692-0514-4CBF-BDCA-E2A3484DB704 Q37229190-0CBEE2E6-42F7-45D4-A7A8-20DD50118914 Q37319733-D1D3DF4C-A742-4284-A272-6DD0DBDCE32A Q37582179-A29F1991-CFC9-4ADE-95F5-39F894AE0704 Q37597172-0E9C7E3F-EF82-4636-BA3C-6F115399AA9D Q37698857-779FF2B9-6AF9-4F55-9D0C-86C96E04CE5E Q38028791-8FC4B1CA-C9CA-4240-AE23-572FEEBAF8C7 Q38074154-10120EFD-4C7D-4EC9-B7B4-F28C1926CBDC Q38155002-3220E3A1-FDA3-4BEF-8B29-1547A8CE7207 Q38264293-849838AF-6E6A-433C-93D5-251176E89C86 Q38447992-C9DB8035-C999-4D71-9C61-4CC8ECD3B09E Q38692500-5270A0B8-1C03-42F6-A30B-18AD7B58BF13 Q38966022-74901BE4-B002-44E0-B44E-8C3D28A8B48E Q39135499-31C2D611-EAD3-4972-B988-F9B6FB750DCC Q39388400-428B6713-908E-4A86-87E9-A56253B14B01 Q39413595-0CE6A9D3-F48F-40FD-8A97-C7F623F5E02D Q42549680-882A65F5-EA3B-4D28-B45F-738F0897BE8F Q47843870-81D1E069-0CEA-4E18-84D1-38084DAFDA94 Q52563042-75B0447E-68AA-41FF-9786-B296E7C636A1

P2860

Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia.

http://www.wikidata.org/entity/Q35382105

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Antiangiogenic agent sunitinib ...... nd suppresses cycling hypoxia.

@ast

Antiangiogenic agent sunitinib ...... nd suppresses cycling hypoxia.

@en

type

label

Antiangiogenic agent sunitinib ...... nd suppresses cycling hypoxia.

@ast

Antiangiogenic agent sunitinib ...... nd suppresses cycling hypoxia.

@en

prefLabel

Antiangiogenic agent sunitinib ...... nd suppresses cycling hypoxia.

@ast

Antiangiogenic agent sunitinib ...... nd suppresses cycling hypoxia.

@en

P1433

Q35382105-90872D5D-A0EE-4C95-BA84-40D85DF6E063

P1476

Q35382105-188C4270-73CA-45C6-8913-D605E6B4D619

P2093

Q35382105-079103BB-EB35-469D-BDB1-273F66F4DE16

Q35382105-3C526107-46A5-4ADA-9DD7-29F0C75E5370

Q35382105-5DED69A9-5773-40D2-9DD6-BEE61111DE28

Q35382105-64AF2415-A7AD-4E47-87FB-ED65A77ACE24

Q35382105-6588BC33-96D1-4FE1-ACF6-57F9160DC3F7

Q35382105-8CD38E35-5E93-4030-BAD0-35E72F999C41

Q35382105-8EBF452A-09ED-400D-8D87-F848D41BFA6F

Q35382105-B062B57A-AFB1-4354-A1E4-5918AE623F47

Q35382105-EA0717B8-C8CE-4841-B2EC-542DBAC64864

Q35382105-F21078A5-24BA-4D92-8876-412A1FED9FE4

P2860

Q35382105-017D8416-E93B-4F2E-9F77-830FC48038DB

Q35382105-01F1A455-2DFA-4B4A-81BE-32C3163A7F82

Q35382105-0C09DB03-B947-4F88-BC3A-51DA10A721C8

Q35382105-1D037911-F984-4574-93CC-2BC14AD65EC4

Q35382105-2833B223-D620-4FC7-99D6-EB8E00ADCB4D

Q35382105-2D490B4B-7D23-4B82-B391-7EAB73F21601

Q35382105-31DFA0F4-1311-4E78-A8C4-3C6648CCC87A

Q35382105-383F9569-A04C-43B2-B567-77A19B3D7D98

Q35382105-389155E5-0D19-4B3B-90DF-B4B5045A5408

Q35382105-3C4DB52E-41AE-4DD8-B62A-1E3E7A9ED839

P304

Q35382105-65B4EEFF-186C-42DB-A93F-4C3E8B4A9CDF

P31

Q35382105-B1B0C9B0-8FF0-4740-A0CA-05B0B3B0A44C

P356

Q35382105-3A2D9843-C4AE-4DC6-B9EE-6DF5AAEE1D6F

P407

Q35382105-DB5EF164-0353-4E90-AFB9-EB212BD6CC96

P433

Q35382105-90C4640B-C788-4AA5-9379-312632EBCA0E

P478

Q35382105-87B1F929-4F8D-4850-B106-64617660181F

P50

Q35382105-5F767AB5-B3B2-4D1F-BFE4-42069F2BC1FA

P577

Q35382105-06C8C751-9B25-4BF8-B08C-08EA9B5BEEB3

P698

Q35382105-4D8310DF-9B94-4D07-835E-8B2424A7D0BB

P921

Q35382105-33F22842-B2B8-4C88-9456-A42DD61F28E1

P932

Q35382105-8A922E99-FB31-41A3-9483-867E806E4930

P356

0008-5472.CAN-11-2025

P1433

Cancer Research

P1476

Antiangiogenic agent sunitinib ...... and suppresses cycling hypoxia

@en

P2093

Chandramouli Gadisetti

http://www.w3.org/2001/XMLSchema#string

James B Mitchell

http://www.w3.org/2001/XMLSchema#string

Jeeva P Munasinghe

http://www.w3.org/2001/XMLSchema#string

Keita Saito

http://www.w3.org/2001/XMLSchema#string

Murali C Krishna

http://www.w3.org/2001/XMLSchema#string

Nallathamby Devasahayam

http://www.w3.org/2001/XMLSchema#string

Rajani Choudhuri

http://www.w3.org/2001/XMLSchema#string

Sankaran Subramanian

http://www.w3.org/2001/XMLSchema#string

Shingo Matsumoto

http://www.w3.org/2001/XMLSchema#string

Sonny Batra

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Tumor angiogenesis: therapeutic implications

Angiogenesis in cancer and other diseases

Why do cancers have high aerobic glycolysis?

Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy

Molecular regulation of vessel maturation

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice.

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.

P304

6350-6359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-2025

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21878530

http://www.w3.org/2001/XMLSchema#string

P921

P932

3196374

http://www.w3.org/2001/XMLSchema#string